Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.68 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.63 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13588800 | 0.99 | HRH3 (0.68) | HRH3KCNH2PSMB1PSMB5ESR1 | |
| SCHEMBL13588807 | 0.86 | CA12 (0.70) | HRH3KCNH2LTA4HALDH1A1KDM4E | |
| SCHEMBL13588805 | 0.86 | LTA4H (0.53) | HRH3KCNH2PSMB1PSMB5ESR1 | |
| SCHEMBL13589529 | 0.82 | HRH3 (0.73) | HRH3KCNH2PSMB1PSMB5LTA4H | |
| SCHEMBL7466649 | 0.80 | HRH3 (1.00) | HRH3KCNH2PSMB1PSMB5LTA4H | |
| SCHEMBL13588808 | 0.79 | NPC1 (0.49) | HRH3KCNH2ESR1ESR2 | |
| SCHEMBL10223295 | 0.78 | PSMB1 (0.82) | HRH3PSMB1PSMB5LTA4HALDH1A1 | |
| Hydrochloric Acid SCHEMBL7653369 | 0.78 | HRH3 (0.68) | HRH3KCNH2PSMB1PSMB5ESR1 | |
| Hydrochloric Acid SCHEMBL7653228 | 0.78 | HRH3 (0.68) | HRH3KCNH2PSMB1PSMB5ESR1 | |
| SCHEMBL7653368 | 0.78 | HRH3 (0.68) | HRH3KCNH2PSMB1PSMB5LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | HRH3 752/4885KCNH2 50/4885PSMB1 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.